• Family of patient who died after orthopedic surgery wins $35M verdict against hospital
  • Orthopedic surgeon wins $20M verdict against Johnson & Johnson
  • Minnesota orthopedic group hit with $111M negligence verdict
  • Orthopedic patient's death highlights potential dangers of prior authorization
  • Spine surgeon's video hits 1 million views on TikTok
  • Spine surgeon killed in Oklahoma hospital shooting
  • Spine surgeon owes $17M to paralyzed patient
  • Providence to pay $22.7M to settle unnecessary spine surgery allegations
  • Spine surgeon gets jail time for abusing patient during hospital visit
  • 'They're on really thin ice': Why 1 insurer has drawn spine surgeons' ire
  • Connecticut hospital to appeal $12.5M verdict to family of patient who died after orthopedic surgery
  • Orthopedic surgeon must face suit in patient's death
  • Spine surgeon 1 of 9 physician billionaires on Forbes' 2022 list
  • 23 spine device companies to watch in 2022
  • 4 spine technologies that promised more than they delivered
  • Orthopedic surgeon salary vs. average household income in each state
  • Orthopedic surgeon's health system exit steeped in controversy
  • Terminated orthopedic surgeon contracts with another New York hospital
  • Orthopedic surgeon convicted of battery at hospital
  • Billionaire spine surgeon buys $23.9M mansion
  • UArizona neurosurgery chair dies after motorcycle collision
  • Texas spine surgeon sued by State Farm over 'unnecessary' procedures
  • The spine tech surgeons say will explode in the next 5 years
  • Could Medtronic's spine business be the next medtech spinoff?
  • Ex-NFL player gets 5 years in prison for $2.9M healthcare fraud scheme
  • 41 'rising stars' in orthopedics
  • Orthopedic surgeon indicted in $10M telemedicine fraud scheme
  • Neurosurgeon's startup hits $1.2B valuation
  • Orthopedic surgeon fined for operating on wrong knee
  • Lawsuits build against Aetna's spine surgery coverage
  • Good news, bad news for orthopedic surgeons: 6 observations
  • Former spine surgeon owes $13M to 2 women over unnecessary procedures
  • Walmart's latest partnership pushes retailer into spine care
  • Texas spine surgeon's $11M verdict being appealed
  • 10 power players in orthopedics
  • Rothman Orthopaedics to become national brand, but no 'aspirations to go beyond US'
  • Sports medicine physician fired amid misconduct allegations involving patients
  • Orthopedic surgeon allegedly exaggerated patient visits to defraud insurers
  • Top orthopedic hospital in every state: US News
  • Orthopedic surgeon asking for misconduct charges to be dropped
  • How Medtronic is strengthening its spine business
  • $85M settlement reached in spinal cord stimulation lawsuits
  • Medtronic's next-gen predictive spine surgery model cleared
  • ZimVie's pediatric scoliosis device gets coverage by Anthem BCBS
  • Spinal fusion alternative device reaches FDA milestone
  • Smith+Nephew CEO focusing on orthopedic ASC market: 11 things to know about Roland Diggelmann

    Smith+Nephew CEO focusing on orthopedic ASC market: 11 things to know about Roland Diggelmann

    Alan Condon -  

    Smith+Nephew CEO Roland Diggelmann is approaching his sixth month as head of the medical device company and turning his attention to the growing orthopedic ASC market this year.

    Here are 11 things to know about Mr. Diggelmann and his tenure as CEO so far:

    1. For the fourth quarter of 2019, Mr. Diggelmann's first quarter as CEO, Smith+Nephew reported $1.4 billion in revenue and $5.1 billion for the full year. Fourth-quarter revenue increased 8.7 percent and full-year revenue rose 4.4 percent.

    2. This year, he aims to boost the company's performance and continue its investment in the developing orthopedics segment in ASCs in the U.S.

    3. Smith+Nephew's operations have been impacted by the COVID-19 outbreak in China but expects the situation to normalize in the second quarter of 2020. China represented 7 percent of the company's revenue in 2019.

    4. Mr. Diggelmann was appointed CEO of Smith+Nephew in November 2019, following in the footsteps of Namal Nawana, who held the position for almost two years.

    5. As CEO, he began with a base salary of about $1.4 million. This year, Mr. Diggelmann will be able to earn up to 150 percent of his base salary in a cash incentive plan, as well as having access to Smith+Nephew's annual equity incentive plan and performance share plan awards.

    6. The Swiss executive began his 25-plus year career in the medical device industry with AllPro AG, a manufacturer of artificial joints.

    7. In 1997, he joined Sulzer Orthopedics, where he rose up the ranks from director of strategic planning and marketing to executive vice president of sales in Europe and Asia Pacific.

    8. After Sulzer Orthopedics, Mr. Diggelmann accepted a position at Zimmer — now Zimmer Biomet — where he served as senior vice president of Europe, the Middle East and the African markets.

    9. Before joining Smith+Nephew, he operated as CEO of Roche Diagnostics, a company he spent 12 years at. He served as COO for seven years and CEO for three years, according to his LinkedIn profile.

    10. Mr. Diggelmann also serves on several company boards, including reproductive genetics company Igenomix, heart screening company HeartForce AG and Accelerate Diagnostics, a diagnostic company for bacterial infections.

    11. He holds a bachelor's degree in business administration from the University of Berne in Switzerland.

    Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

    Featured Learning Opportunities

    Featured Webinars

    Featured Podcast

    Featured Whitepapers